The overall aims of the Clinical Protocol and Data Management Shared (CPDM) Facility are to: a) provide central management for the implementation, coordination, and conduct of clinical trials developed by the UAB Cancer Center faculty and by our extramural collaborators associated with SPOREs, other Cancer Centers, the NCI, industry and cooperative groups, b) provide for quality assurance of the operation including monitoring of toxicities, clinical care, data collection, and adherence to protocol-described procedures, c) provide a centralized database of protocol-specific data, and d) provide research pharmacy support for the acquisition, storage, dispensing, and tracking of all investigational agents administered to protocol patients as required by the protocol and regulatory agencies (local, state, and national). Major accomplishments since last submission have included: a) An increment of 28% in the 4 year accrual of patients in the CPDM Facility. This patient accrual includes a total of 1047 patients to investigator initiated trials (34% of the total accrual) and 1305 patients to Phase I and II trials (42% of the total accrual), b) Implementation of the Clinical Trials Monitoring Committee (CTMC) which meets weekly and monitors every active clinical trial in the Cancer Center, c) Development of specialized Protocol Management Teams consisting of nurse protocol coordinators and data managers to improve their disease specific expertise, enhance nurse-physician interaction and to increase the number of patients enrolled in the high priority studies, d) During this funding period, the Cancer Center played a central role in recruitment of 16 clinical investigators to UAB clinical Divisions and Departments. These recruitments ncluded the Deputy Director of the Cancer Center (Dr. Bland), Associate Director for Clinical Research (Dr. Rinehart) and Medical Director of the CPDM Facility (Dr. Forero). e) In 2002, we developed full ECOG membership under the leadership of Carla Falkson, M.D. In 2003, our first year of full membership we became the leading accrual site for ECOG with over 100 registrations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA013148-36
Application #
7414807
Study Section
Subcommittee G - Education (NCI)
Project Start
2007-05-01
Project End
2010-03-31
Budget Start
2007-05-01
Budget End
2008-03-31
Support Year
36
Fiscal Year
2007
Total Cost
$405,960
Indirect Cost
Name
University of Alabama Birmingham
Department
Type
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Williams, Adele P; Waters, Alicia M; Stewart, Jerry E et al. (2018) A novel retinoid X receptor agonist, UAB30, inhibits rhabdomyosarcoma cells in vitro. J Surg Res 228:54-62
Carson, Tiffany L; Wang, Fuchenchu; Cui, Xiangqin et al. (2018) Associations Between Race, Perceived Psychological Stress, and the Gut Microbiota in a Sample of Generally Healthy Black and White Women: A Pilot Study on the Role of Race and Perceived Psychological Stress. Psychosom Med 80:640-648
McCaw, Tyler R; Randall, Troy D; Arend, Rebecca C (2018) Overcoming immune suppression with epigenetic modification in ovarian cancer. Transl Res :
Frugé, Andrew D; Cases, Mallory G; Howell, Carrie R et al. (2018) Fingernail and toenail clippings as a non-invasive measure of chronic cortisol levels in adult cancer survivors. Cancer Causes Control 29:185-191
Samykutty, Abhilash; Grizzle, William E; Fouts, Benjamin L et al. (2018) Optoacoustic imaging identifies ovarian cancer using a microenvironment targeted theranostic wormhole mesoporous silica nanoparticle. Biomaterials 182:114-126
Geng, Mengxin; Austin, Frank; Shin, Ronald et al. (2018) Covalent Structure and Bioactivity of the Type AII Lantibiotic Salivaricin A2. Appl Environ Microbiol 84:
Powell, T Clark; Dilley, Sarah E; Bae, Sejong et al. (2018) The Impact of Racial, Geographic, and Socioeconomic Risk Factors on the Development of Advanced-Stage Cervical Cancer. J Low Genit Tract Dis 22:269-273
Friedman, Gregory K; Bernstock, Joshua D; Chen, Dongquan et al. (2018) Enhanced Sensitivity of Patient-Derived Pediatric High-Grade Brain Tumor Xenografts to Oncolytic HSV-1 Virotherapy Correlates with Nectin-1 Expression. Sci Rep 8:13930
Subramaniam, Akila; Blanchard, Christina T; Erickson, Britt K et al. (2018) Feasibility of Complete Salpingectomy Compared With Standard Postpartum Tubal Ligation at Cesarean Delivery: A Randomized Controlled Trial. Obstet Gynecol 132:20-27
Kasten, Benjamin B; Oliver, Patsy G; Kim, Harrison et al. (2018) 212Pb-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models. Int J Mol Sci 19:

Showing the most recent 10 out of 747 publications